Goldman Sachs Maintains Neutral on Tarsus Pharmaceuticals, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan maintains a Neutral rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raises the price target from $19 to $30.
February 29, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on Tarsus Pharmaceuticals but increases the price target from $19 to $30.
The increase in price target by a reputable analyst firm like Goldman Sachs suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term rise in stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90